- Misonix (MSON +0.4%) has announced that the second largest U.S. Commercial payer will now cover TheraSkin, cellular and tissue-based treatment for all lower extremity dermal wounds, including venous leg ulcers and diabetic foot ulcers.
- The company says that with this new coverage, it can now have additional 32M covered lives.
- https://seekingalpha.com/news/3645777-misonixs-theraskin-to-be-covered-u-s-commercial-payer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.